Combinatorial gene therapy renders increased survival in cirrhotic rats

Journal of Biomedical Science

Volumn 17, Issue 1, 2010, Pages

  Gálvez Gastélum, Francisco J ^a   Segura Flores, Aida A ^a   Senties Gomez, María D ^a   Muñoz Valle, Jose F ^a   Armendáriz Borunda, Juan S ^a,b  

^a UNIVERSITY OF GUADALAJARA   (Mexico)

^b HOSPITAL CIVIL DE GUADALAJARA FRAY ANTONIO ALCALDE   (Mexico)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOVIRUS VECTOR; BETA GALACTOSIDASE; CARBON TETRACHLORIDE; HYDROXYPROLINE; MINERAL OIL; NEUTROPHIL COLLAGENASE; SMOOTH MUSCLE ACTIN; TRANSFORMING GROWTH FACTOR BETA1; UROKINASE; MMP8 PROTEIN, HUMAN; PRIMER DNA; RECOMBINANT PROTEIN;

ADENOVIRIDAE; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG LIVER LEVEL; EXPERIMENTAL LIVER FIBROSIS; GENE EXPRESSION; INTOXICATION; LIVER CIRRHOSIS; NONHUMAN; OVERALL SURVIVAL; PRIORITY JOURNAL; RAT; SURVIVAL INDEX; SURVIVAL RATE; SURVIVAL TIME; VIRAL GENE DELIVERY SYSTEM; VIRAL GENE THERAPY; WISTAR RAT; ADENOVIRUS; ANIMAL; CHEMICALLY INDUCED DISORDER; EXPERIMENTAL LIVER CIRRHOSIS; GENE THERAPY; GENE VECTOR; GENETICS; HUMAN; IMMUNOHISTOCHEMISTRY; LIVER; LIVER REGENERATION; METABOLISM; NUCLEOTIDE SEQUENCE; PATHOLOGY; PHYSIOLOGY;

ADENOVIRIDAE; ANIMALS; BASE SEQUENCE; CARBON TETRACHLORIDE; DNA PRIMERS; GENE EXPRESSION; GENE THERAPY; GENETIC VECTORS; HUMANS; IMMUNOHISTOCHEMISTRY; LIVER; LIVER CIRRHOSIS, EXPERIMENTAL; LIVER REGENERATION; MATRIX METALLOPROTEINASE 8; RATS; RATS, WISTAR; RECOMBINANT PROTEINS; UROKINASE-TYPE PLASMINOGEN ACTIVATOR;

EID: 77952702034     PISSN: 10217770     EISSN: 14230127     Source Type: Journal    
DOI: 10.1186/1423-0127-17-42     Document Type: Article

References (20)

1. Sistema Nacional de Información en Salud - Mortalidad [http://sinais.salud.gob.mx/mortalidad/]. Accessed 28 May 2010
2. Bataller R, Brenner DA: Liver fibrosis. J Clin Invest 2005, 115(2):209-18.
3. Rodríguez Hernández H, Jacobo Karam JS: Supervivencia de pacientes con cirrosis hepática en el Hospital General Regional del IMSS, Durango. Gaceta Medica de México 2002, 138:325-330.
4. Henderson NC, Iredale JP: Liver fibrosis: cellular mechanisms of progression and resolution. Clin Sci (Lond) 2007, 112(5):265-80.
5. Iredale JP: Models of liver fibrosis: exploring the dynamic nature of inflammation and repair in a solid organ. J Clin Invest 2007, 117(3):539-48.
6. Friedman SL: Mechanisms of disease: Mechanisms of hepatic fibrosis and therapeutic implications. Nat Clin Pract Gastroenterol Hepatol 2004, 1(2):98-105.
7. Agamennone M, Campestre C, Preziuso S, Consalvi V, Crucianelli M, Mazza F, Politi V, Ragno R, Tortorella P, Gallina C: Synthesis and evaluation of new tripeptide phosphonate inhibitors of MMP-8 and MMP-2. Eur J Med Chem 2005, 40(3):271-9.
8. Hemmann S, Graf J, Roderfeld M, Roeb E: Expression of MMPs and TIMPs in liver fibrosis - a systematic review with special emphasis on antifibrotic strategies. J Hepatol 2007, 46(5):955-75.
9. Siller-López F, Sandoval A, Salgado S, Salazar A, Bueno M, Garcia J, Vera J, Gálvez J, Hernández I, Ramos M, Aguilar-Cordova E, Armendariz-Borunda J: Treatment with human metalloproteinase-8 gene delivery ameliorates experimental rat liver cirrhosis. Gastroenterology 2004, 126(4):1122-33. discussion 949
10. Gonzalez-Cuevas J, Bueno-Topete M, Armendariz-Borunda J: Urokinase plasminogen activator stimulates function of active forms of stromelysin and gelatinases (MMP-2 and MMP-9) in cirrhotic tissue. J Gastroenterol Hepatol 2006, 21(10):1544-54.
11. Lin Y, Xie WF, Chen YX, Zhang X, Zeng X, Qiang H, Chen WZ, Yang XJ, Han ZG, Zhang ZB: Treatment of experimental hepatic fibrosis by combinational delivery of urokinase-type plasminogen activator and hepatocyte growth factor genes. Liver Int 2005, 25(4):796-807.
12. Garcia-Bañuelos J, Siller-Lopez F, Miranda A, Aguilar LK, Aguilar-Cordova E, Armendariz-Borunda J: Cirrhotic rat livers with extensive fibrosis can be safely transduced with clinical-grade adenoviral vectors. Evidence of cirrhosis reversion. Gene Ther 2002, 9(2):127-34.
13. Perez Tamayo R: Is cirrhosis of the liver experimentally produced by CCl4 and adequate model of human cirrhosis? Hepatology 1983, 3(1):112-20.
14. Salgado S, Garcia J, Vera J, Siller F, Bueno M, Miranda A, Segura A, Grijalva G, Segura J, Orozco H, Hernandez-Pando R, Fafutis M, Aguilar LK, Aguilar-Cordova E, Armendariz-Borunda J: Liver cirrhosis is reverted by urokinase-type plasminogen activator gene therapy. Mol Ther 2000, 2(6):545-51.
15. Rojkind M, Gonzalez E: An improved method for determining specific radioactivities of proline-14C and hydroxyproline-14C in collagen and in noncollagenous proteins. Anal Biochem 1974, 57(1):1-7.
16. Jepsen P, Vilstrup H, Andersen PK, Lash TL, Sørensen HT: Comorbidity and survival of Danish cirrhosis patients: a nationwide population-based cohort study. Hepatology 2008, 48(1):214-20.
17. Tiberio GA, Tiberio L, Benetti A, Cervi E, Montani N, Dreano M, Garotta G, Cerea K, Steimberg N, Pandolfo G, Ferrari-Bravo A, Mazzoleni G, Giulini SM, Schiaffonati L: IL-6 Promotes compensatory liver regeneration in cirrhotic rat after partial hepatectomy. Cytokine 2008, 42(3):372-8.
18. Armendariz-Borunda J: Genomic medicine in Mexico. Applications of gene therapy for cirrhosis reversion. Ann Hepatol 2002, 1(4):169-74.
19. Matsuno Y, Iwata H, Umeda Y, Takagi H, Mori Y, Kosugi A, Matsumoto K, Nakamura T, Hirose H: Hepatocite growth factor gene transfer into the liver via the portal vein using electroporation attenuates rat liver cirrhosis. Gene Therapy 2003, 10:1559-1566.
20. Bueno M, Salgado S, Beas-Zárate C, Armendariz-Borunda J: Urokinase-type plasminogen activator gene therapy in liver cirrhosis is mediated by collagens gene expression down-regulation and up-regulation of MMPs, HGF and VEGF. J Gene Med 2006, 8(11):1291-9.